Gilde Healthcare leads EUR 40 Million financing in Irish healthtech company FIRE1 - Gilde Healthcare

Gilde Healthcare leads EUR 40 Million financing in Irish healthtech company FIRE1

30 januari 2018

Dublin, Ireland – Foundry Innovation & Research 1, Ltd. (“FIRE1”), today announced the close of a Series C financing totaling EUR 40 Million
($48.5 Million). The financing was led by Gilde Healthcare with the participation of Gimv, Seventure, New Enterprise Associates, Lightstone Ventures and Medtronic. It was also announced that Janke Dittmer, partner at Gilde Healthcare has joined FIRE1’s Board of Directors.

The financing provides FIRE1 with capital to further advance remote monitoring to improve outcomes for heart failure patients. Managing patients at home with novel digital health-enabled solutions will help intercept the disease trajectory and reduce hospitalizations. Nearly six million Americans live with heart failure, a number that is expect to increase to more than eight million by 2030. Globally, it is estimated that at least 26 million people suffer from heart failure, and the burden is particularly high for older patients. It is the leading cause of hospitalization for people over 65, with annual treatment costs exceeding $31 billion in the U.S. alone. With an aging population, the impact of heart failure is expected to increase substantially.

About FIRE1
Headquartered in Dublin, Ireland, FIRE1 is a connected medical device solutions company dedicated to improving outcomes for people suffering with chronic diseases. Its first product is a novel remote monitoring solution to improve outcomes for Heart Failure patients. The FIRE1 team is led by an experienced medical devices team who are working closely with researchers, clinicians, patients and payors to help reduce the burden of heart failure. For more information, please visit www.fire1foundry.com

About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. Gilde Healthcare’s venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Netherlands, Belgium and Germany. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market. Since 2001 Gilde Healthcare has raised EUR 800 million (USD 1 billion) for its specialized funds. Gilde is currently investing out of Gilde Healthcare IV which is financed, in part, by the European Recovery Program-European Investment Fund Facility. For more information, visit the company’s website at www.gildehealthcare.com

Gilde Healthcare Contact:
Janke Dittmer
healthcare@gildehealthcare.com

Gilde Healthcare participates in $150M Series D financing of CatalYm

Proceeds will expand late-stage clinical development of lead programme visugromab’s into earlier lines of treatment including checkpoint naïve and second-line settings in randomized, controlled studies in select solid tumor indications Round brings on board new international...
16 juli 2024

Gilde Healthcare portfolio company Eetgemak joins forces with TotaalVERS to become the leading integrated healthcare foodservice provider

Combining TotaalVERS and Eetgemak will form a leading end-to-end foodservice provider*, offering a wide range of convenience meals, ingredients and groceries to the healthcare sector. The partnership emphasizes commitment to quality, service, and innovation in...
5 juli 2024

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
21 mei 2024